logo
Oasis Announces a Second Campaign -- A Decade After the First -- to Create A Better Kyocera

Oasis Announces a Second Campaign -- A Decade After the First -- to Create A Better Kyocera

Business Wire15-05-2025

HONG KONG--(BUSINESS WIRE)--Oasis Management Company Ltd. ('Oasis') is manager to funds that beneficially own shares in Kyocera Corporation (6971 JP) ('Kyocera' or the 'Company'). Oasis has adopted the Japan FSA's 'Principles of Responsible Institutional Investors' (a.k.a. the Japan Stewardship Code) and in line with those principles, Oasis monitors and engages with its investee companies.
Oasis first approached Kyocera in 2015 with proposals to divest loss-making businesses and reduce cross-shareholdings in order to achieve a much-needed turnaround, but the Company failed to implement any of these suggestions. Since then, Kyocera's stagnation and weak performance has only become more evident, to the frustration of all stakeholders.
Support for Kyocera's management plummeted at its Annual General Meeting (AGM), with the approval rate for the Company President falling from 96% in 2015 to just 65% in 2023. In response, management has recently announced reforms, including divesting underperforming businesses (representing 10% of revenue), selling one-third of its KDDI shares, and implementing JPY400bn in buybacks over the next four years.
Unfortunately, we believe these reforms are inadequate and do not address the Company's key issues. Whilst Kyocera has excellent technical capabilities in its core businesses, including Ceramic Packages and Fine Ceramic Components, Kyocera has failed to maximize on opportunities in its core businesses due to over diversification and subsequent lack of focus. Managing such a diverse array of businesses has made agile decision-making nearly impossible and has limited Kyocera's ability to develop effective business strategies.
As a result, Kyocera has fallen behind its specialist competitors as reflected by its effectively flat stock price over the last ten years compared to Maruwa Co., Ltd., TDK Corporation, and Ibiden Co., Ltd., which saw gains of +1,118%, +191%, and +159% respectively over the same period.
Kyocera's plan to sell one-third of its KDDI holdings and implement a JPY400 billion buyback over the next two years appears to be reactionary rather than carefully considered. Kyocera owns cross-shareholdings of over JPY1.7 trillion, including its 15.29% stake in KDDI, and received a total dividend of almost JPY50 billion in the last fiscal year. We believe that, in the short-term, Kyocera should use a mix of leverage and sales of cross-shareholdings to finance JPY1 trillion of buybacks over the next four years.
Without deeper reforms, Kyocera's ROE will likely remain under 5% and cross-shareholdings, as a proportion of shareholders' equity, will remain far above the ISS threshold of 20% of net assets, leading to lower approval ratings as shareholders demand ever increasing accountability for operational performance, capital efficiency and improved corporate governance.
To address these issues, Oasis urges Kyocera to implement the following seven-point plan:
Divest non-core businesses amounting to over JPY660 billion of revenue.
Exit the Organic Packages to prevent further losses.
Restructure its KAVX subsidiary to achieve higher margins in line with peers.
Stop losses by halting investment into GaN and millimeter-wave technologies which have little potential to produce material returns.
Focus on its core business such as ceramics to capture untapped opportunities.
Commit to aggressive M&A to reinforce core businesses.
Announce a buyback program of JPY1 trillion over the next four years, amounting to approximately 37% of the Company.
By implementing this plan, we believe that the stock could see an upside of over 90% from current levels.
Seth Fischer, Founder & Chief Investment Officer of Oasis, said:
" Kyocera's excessive diversification has prevented it from long realizing its full potential. The Company continues to support underperforming businesses while failing to prioritize investment and growth opportunities within its best businesses such as ceramics packaging, and the automotive and semiconductor sectors. With cross-shareholdings still accounting for 53% of its net assets and an ROE of just 0.8%, the time for meaningful change is now.
Management needs to address the twin problems of over-diversification and over-capitalization of its balance sheet by exiting underperforming businesses, leaning into its best growth opportunities, and taking a much more ambitious stance on unwinding cross-shareholdings to improve returns on capital."
Full details can be viewed on the homepage of abetterkyocera.com. All stakeholders are encouraged to contact Oasis at info@abetterkyocera.com.
***
Oasis Management Company Ltd. manages private investment funds focused on opportunities in a wide array of asset classes across countries and sectors. Oasis was founded in 2002 by Seth H. Fischer, who leads the firm as its Chief Investment Officer. More information about Oasis is available at https://oasiscm.com. Oasis has adopted the Japan FSA's 'Principles for Responsible Institutional Investors' (a.k.a. the Japan Stewardship Code) and, in line with those principles, Oasis monitors and engages with our investee companies.
The information and opinions contained in this press release (referred to as the "Document") are provided by Oasis Management Company ('Oasis') for informational or reference purposes only. The Document is not intended to solicit or seek shareholders to, jointly with Oasis, acquire or transfer, or exercise any voting rights or other shareholder's rights with respect to any shares or other securities of a specific company which are subject to the disclosure requirements under the large shareholding disclosure rules under the Financial Instrument and Exchange Act. Shareholders that have an agreement to jointly exercise their voting rights are regarded as Joint Holders under the Japanese large shareholding disclosure rules and they must file notification of their aggregate shareholding with the relevant Japanese authority for public disclosure under the Financial Instruments and Exchange Act. Except in the event that Oasis expressly enters into the agreement as a joint holder requiring such disclosure, Oasis does not intend to take any action triggering reporting obligations as a Joint Holder. The Document exclusively represents the opinions, interpretations, and estimates of Oasis.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting
Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting

Business Wire

timea day ago

  • Business Wire

Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting

NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC ('Mason'), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. ('Grifols' or the 'Company') (BME: GRF) (NASDAQ: GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the 'Board') expressing Mason's support for the Company's recommended slate of director candidates for election at the Ordinary General Shareholders' Meeting to be held on June 4 and 5, 2025. The full text of the letter follows: Grifols, S.A. Avinguda de la Generalitat 152-158 08174 Sant Cugat del Vallès Barcelona – SPAIN Dear Grifols Board Members: Mason Capital owns ~3% of Grifols A shares. We are aligned with the current Board and are supportive of the recommended slate of director candidates for election at the AGM. We appreciate the constructive dialogue with Board members to date, particularly Tomas Daga, the retiring Thomas Glanzmann, and the incoming chairwoman Anne Berner. Grifols has amalgamated world class assets over its long history and benefits from an excellent management team that is executing on an achievable 5-year plan. Mason believes board leadership continuity and continued management focus will lead to a much higher stock price over time, as more long-only investors engage with Grifols shares. Regards, Kenneth M Garschina Managing Member Mason Capital Management About Mason Capital Management LLC Mason Capital Management LLC is an absolute return focused investment firm that combines deep fundamental analysis with hard catalysts to drive value creation. Founded in July 2000 by Ken Garschina and Mike Martino, Mason's strategies range from event-driven investing to corporate carve-outs and control acquisitions.

Correction: Bulletin from Sivers Semiconductors AB (publ)'s Annual General Meeting on 28 May 2025
Correction: Bulletin from Sivers Semiconductors AB (publ)'s Annual General Meeting on 28 May 2025

Yahoo

timea day ago

  • Yahoo

Correction: Bulletin from Sivers Semiconductors AB (publ)'s Annual General Meeting on 28 May 2025

NEW YORK, May 30, 2025 /PRNewswire/ -- The correction pertains to the resolution regarding the Board remuneration. In all other respects, the press release remains unchanged. The correct version of the press release is published in its entirety below: The Annual General Meeting in Sivers Semiconductors AB (publ) (the "Company") has been held on 28 May 2025 and in particular the following decisions were resolved. Adoption of the annual report and the auditor's report The Annual General Meeting resolved to approve the profit and loss statement and the balance sheet regarding the parent Company and the Group, appropriation of the profit in accordance with the Board of Directors proposal and not to distribute any dividends for the financial year 2024, as well as to discharge the CEO and Board members from liability. Election of Board members As members of the Board of Directors it was resolved to re-elect Bami Bastani, Tomas Duffy, Erik Fällström, Karin Raj, Todd Thomson and Keith Halsey. Bami Bastani was re-elected as the Chairman of the Board of Directors and Tomas Duffy was re-elected as the Vice Chairman of the Board of Directors. It was resolved that remuneration to the members of the Board of Directors be paid as follows: SEK 1,050,000 to the Chairman of the Board of Directors, SEK 600,000 to the Vice Chairman of the Board of Directors, and SEK 350,000 to each of the other members of the Board of Directors elected by the Annual General Meeting. Remuneration shall amount to SEK 100,000 per year to the Chairman of the Audit Committee and SEK 50,000 per year to each of the other members of the Audit Committee, SEK 60,000 per year to the Chairman of the Investment Committee and SEK 30,000 per year to each of the other members of the Investment Committee, and SEK 50,000 per year to the Chairman of the Remuneration Committee and SEK 25,000 per year to each of the other members of the Remuneration Committee. Furthermore, it was resolved that the Company shall ensure that the Chairman of the Board of Directors is covered by US health insurance. Election of auditor The Annual General Meeting resolved to re-elect Deloitte AB as auditor with authorised public accountant Alexandros Kouvatsos as auditor-in-charge. The fees shall be paid in accordance with approved invoices. Resolution on guidelines for remuneration of senior executives The Annual General Meeting resolved on guidelines for remuneration to senior executives, to apply until further notice. Resolution on a long-term incentive program The Annual General Meeting resolved to introduce an incentive program (the "P10") for employees of the Group. P10 can be allotted to employees in the United States, Scotland, Sweden and India. P10 can be allotted to employees in the United States, Scotland, Sweden and India. P10 consists of stock options intended for the employees of the Group (the "Stock Options"). P10 shall consist of a maximum of 11,100,000 new Stock Options entitling to purchase of the same number of shares in the Company, corresponding to approximately 4.1 per cent of the share capital and votes in the Company after dilution. The Annual General Meeting resolved to authorise the Board of Directors to offer employees of the Group, at the discretion of the Board of Directors, to swap all but not some options granted under prior option grants for options granted under P10 terms and in addition to the maximum number of options described above, whereby two options under prior option grants may be swapped for one option under P10 terms. If all employees to be offered to swap options is accepting the offer, it is estimated the overall dilution for all outstanding incentive programs, including P10, will be reduced from approximately 9 per cent to approximately 6 per cent. The final number of Stock Options that participants in Europe are eligible to exercise may at the Board of Directors' discretion be dependent on performance criteria based on Compound Annual Growth Rate (CAGR) in line with semiconductor industry's growth, currently forecasted at 7.64 per cent. Stock Options granted to participants in the US or India shall not be subject to performance conditions. Resolution to authorise the Board of Directors to resolve on directed issue of Series C shares The Annual General Meeting resolved to authorise the Board of Directors to, on one or more occasions until the next Annual General Meeting, to resolve on a new issue of no more than 11,100,000 Series C shares, each with a quota value of SEK 0.50, corresponding to approximately 4.1 per cent of the share capital and votes of the Company after dilution. With the deviation from the shareholders' preferential rights, the new shares may be subscribed for by a bank or securities company at a subscription price corresponding to the quota value. The purpose of the authorisation and the reason for the deviation from the shareholders' preferential rights in the event of implementation of the share issue is to ensure delivery of shares to participants under the Company's outstanding incentive programs and in order to on terms of liquidity to secure social security charges. Resolution to authorise the Board of Directors to resolve on repurchase of Series C shares and transfer of ordinary shares to secure payment of social security charges The Annual General Meeting resolved to authorise the Board of Directors to, on one or more occasions until the next Annual General Meeting, to resolve on repurchases of Series C shares. Repurchases may only be made through an acquisition offer addressed to all holders of Series C shares and shall comprise all outstanding Series C shares. Acquisitions shall be made at a price corresponding to the quota value of the shares. Payment for acquired shares shall be made in cash. The purpose of the repurchase is to ensure delivery of shares to participants under the Company's outstanding incentive programs and in terms of liquidity to secure social security charges related to such incentive programs. Further, the Annual General Meeting resolved to authorise the Board of Directors to resolve, on one or several occasions until the next Annual General Meeting, to transfer own ordinary shares in accordance with the following. Transfers of ordinary shares may be carried out on Nasdaq Stockholm, at a price within the price range applicable, i.e. the range between the highest purchase price and the lowest selling price. Transfers may be made with the highest amount of ordinary shares required in order for the Company in terms of liquidity to secure social security charges related to the outstanding incentive programs in the Company. Transfer of shares may also take place outside of Nasdaq Stockholm to a bank or securities company, with deviation from the shareholders' preferential rights. Such a transfer may be made at a price corresponding the share price at the time for the transfer on the ordinary shares transferred with such a market discount as the Board of Directors deem appropriate. The authorisation may be used on one or more occasions, although at the latest before the next Annual General Meeting. Resolution on authorisation for the Board of Directors to resolve on issues of shares and/or convertible bonds The Annual General Meeting resolved to authorise the Board of Directors to, on one or several occasions during the period until the next Annual General Meeting, with or without deviation from the shareholder's preferential rights, resolve on share issues and/or issues of convertible bonds that involve the issue of or conversion to a maximum of 47,900,000 ordinary shares, corresponding to a dilution of approximately 15.0 per cent of the share capital and the voting rights after dilution, based on the current number of ordinary shares in the Company. Payment for subscribed shares and/or convertible bonds shall be made in cash, in kind or by way of set-off. The issuance of shares and/or convertible bonds under this authorisation shall be made at a subscription price according to the prevailing market conditions at the time of the issuance of the shares and/or convertible bonds. About Sivers Semiconductors Sivers Semiconductors is a critical enabler of a greener data economy with energy efficient photonics & wireless solutions. Our differentiated high precision laser and RF beamformer technologies help our customers in key markets such as AI Datacenters, SATCOM, Defense and Telecom solve essential performance challenges while enabling a much greener footprint. For additional information, please visit us at: ( CONTACT: Media Contact Tyler Weiland Shelton Group+1-972-571-7834tweiland@ Company ContactVickram VathulyaCEOir@ This information was brought to you by Cision View original content: SOURCE Sivers Semiconductors Sign in to access your portfolio

Sanjivani Paranterals Ltd (BOM:531569) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ...
Sanjivani Paranterals Ltd (BOM:531569) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ...

Yahoo

timea day ago

  • Yahoo

Sanjivani Paranterals Ltd (BOM:531569) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ...

Release Date: May 27, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Sanjivani Paranterals Ltd (BOM:531569) reported a strong revenue growth of 41.3% year-on-year for Q4 FY25, driven by new products and volume expansion. The company successfully underwent multiple regulatory audits and received site approval from a Francophone African nation, opening new market opportunities. The Pune facility is operational with a robust order book covering the next 90 days, marking a strategic milestone in strengthening the company's presence in the IV fluid market. The Prague joint venture has initiated commercial operations with promising early responses, positioning it for significant expansion in FY26. Sanjivani Paranterals Ltd (BOM:531569) plans to launch 15 to 20 new products in FY26, expanding its product portfolio and market reach. The evolving US tariff environment introduces uncertainty, potentially impacting capital expenditure decisions. Global currency markets remain sensitive to recent developments, which may lead to continual volatility. The company faces high barriers to entry in the IV business due to manufacturing complexities and transportation constraints. Capacity utilization at the Mumbai and Dehraun plants is currently at 65% and 40% respectively, indicating room for improvement. The company did not provide specific guidance on future growth rates, creating uncertainty about maintaining current growth momentum. Warning! GuruFocus has detected 3 Warning Signs with BOM:531569. Q: Is the growth momentum of 30% expected to continue next year? A: The broader outlook will be available during the AGM. We are trying our best to maintain growth, but cannot confirm the same speed right now. Unidentified_6 Q: What is the current capacity utilization percentage? A: The capacity utilization for the Mumbai plant is around 65%, and for the Dehradun plant, it stands at 40%. Unidentified_3 Q: What product segments are likely to drive growth for the company in the next 12 years? A: We will continue to expand in existing therapeutic areas such as central nervous system, cardiovascular, anti-diabetic, and anti-allergic. Unidentified_3 Q: Can you provide clarity about the HAL and Prague JVs? A: The Prague facility is focused on nutraceuticals, offering white labeling services. The Pune facility is ready, and commercial production should begin soon. Unidentified_3 Q: What is the outlook for F526 in terms of revenue and margins? A: We won't share exact margins now, but we expect to maintain the same range in terms of revenue and profit. Unidentified_4 For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store